Leveraging more than 25 years of experience, Rob Freedman provides a wide range of corporate and securities legal services to innovative late-stage and public companies in the life sciences and technology industries. He represents issuers and underwriters in IPOs, follow-on offerings and private placements of equity and debt securities. Rob also advises boards and management as an outside general counsel on day-to-day corporate and securities matters, including corporate governance, public company reporting, and stock exchange rules and requirements.

Rob co-chairs Fenwick’s capital markets and public companies group, helping clients raise capital, navigate risk, and tell a story through filings and disclosures over the long term. For example, he represented Loxo Oncology in its IPO, multiple follow-on offerings and its $8 billion acquisition by Eli Lilly. He has also represented Dexcom, a leader in continuous glucose monitoring, for more than 15 years, from its IPO in 2005 to numerous public and private offerings of equity and debt. Rob is committed to a company’s myriad legal needs through its full lifecycle.

Ranked as a top capital markets lawyer by Chambers USA and Chambers Global, Rob is regularly sought after for his thought leadership. He is a lead author of the firm’s Technology and Life Sciences IPO Survey and co-chairs the Practising Law Institute’s How to Prepare an Initial Public Offering 2019 program.

Representative Initial Public Offerings
- Aeglea BioTherapeutics
- AnaptysBio
- Audentes Therapeutics
- Castlight Health
- Corium International
- Cowen and Company
- Dermira
- Dexcom
- Goldman Sachs
- Loxo Oncology
- Morphic Holding
- Obalon Therapeutics
- Piper Jaffray
- Passage Bio
- ServiceNow
- Shutterfly
- Sierra Oncology
- Silver Spring Networks
- Stoke Therapeutics
- Sutro Biopharma
- Upwork
Representative Mergers and Acquisitions
- Loxo Oncology in its $8B acquisition by Eli Lilly
- OncoGenex Pharmaceuticals in its merger with Achieve Life Science
- Castlight Health in its acquisition of Jiff
- Corium in its $504M acquisition by Gurnet Point Capital
- KalVista Pharmaceuticals in its share purchase agreement with Carbylan Therapeutics
- Dexcom in its acquisition of SweetSpot Diabetes Care
- Zappos.com in its $847M acquisition by Amazon.com
- Alpha Innotech in its acquisition by Cell Biosciences
- Data Domain in its $2.4B acquisition by EMC
- Cisco Systems in its $3.2B acquisition of WebEx Communications
- Macromedia in its $3.4B merger with Adobe
Recent Awards and Recognition
- Chambers Global ranked Rob as a top capital markets lawyer (2020)
- Highlighted among the United States’ leading lawyers for capital markets work by The Legal 500 (2020)
- Best Lawyers named Rob among “The Best Lawyers in America” for his work in corporate law and securities and capital markets law (2020)
- Chambers USA ranked Rob as a top capital markets lawyer (2019 – 2020)
- LMG Life Sciences recognized Rob as a Star (2019)
- US News recognized Rob for his excellence in securities and capital markets law and corporate law (2019)
- The Legal 500 recognized Rob for his capital markets practice (2016 – 2020 )

Clients praise Rob’s “very good technical skill set, terrific work and very up-to-date advice on complex capital markets transactions.”

—Chambers USA, Client Quote 2020 Edition

Professional Achievements

Chambers Global and Chambers USA ranked Rob as a top capital markets lawyer (2020)
Best Lawyers named Rob among “The Best Lawyers in America” for his work in corporate law and securities and capital markets law (2020)